ArticleEJNMMI physics2026
Fast [
Article in EJNMMI physics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
purposeWhole-body post-therapy SPECT/CT plays an important role in [177Lu]Lu-PSMA-617 (LuPSMA) radiopharmaceutical therapy for verifying biodistribution, assessing treatment response, and performing radiation dosimetry. However, conventional dual-head NaI(Tl)-based scanners typically require lengthy scans, which can be resource-intensive and challenging for patient compliance, limiting their routine use in clinical practice. This study explores reducing acquisition duration using dual-energy peaks to increase count statistics and Monte Carlo-based scatter correction (MCS) to maintain image quality and quantitative accuracy under low-count conditions.
methodsLuPSMA scans (33 studies from 29 patients) covering mid-thigh to vertex (3 bed positions) were acquired using a dual-head NaI(Tl)-based scanner (Siemens Intevo) with both 208 and 113 keV photopeaks and corresponding scatter windows. Full-duration 12 min/bed acquisitions were reconstructed using MCS (Hermia SPECT Reconstruction, Hermes) and the scanner’s energy-window-based scatter correction (EWS), where MCS reconstruction at 12 min/bed served as the reference standard. Shorter-duration projections (1.5, 3, and 6 min/bed) were synthetically generated and reconstructed using MCS. Image quality metrics, including bias, coefficient of variation (CV), contrast ratio (CR), and signal-to-noise ratio (SNR), were evaluated across segmented organs and tumors.
resultsMCS reconstructions at 1.5–6 min/bed showed < 6% bias in mean organ uptake (median ~ 2%) relative to the 12 min/bed MCS (reference), significantly lower (p < 0.01) than the bias for 12 min/bed EWS (median ~ 3%). For mean tumor uptake, 3–6 min/bed MCS showed < 10% bias (median ~ 5%), with no significant difference from 12 min/bed EWS (median ~ 6%). CR remained consistent across all reconstructions (median ~ 5). MCS at 12 min/bed had slightly better CV, CR, and SNR than EWS at 12 min/bed, though differences were not statistically significant. MCS at 6 min/bed was not significantly different from either full-duration reconstruction. Visual assessments supported these findings, with MCS benefits over EWS more pronounced at lower count levels.
conclusionThese findings indicate that using dual-energy acquisition with MCS, scan times as short as 3–6 min/bed on conventional NaI(Tl)-based scanners maintain sufficient image quality for lesion detection, therapy monitoring, and dosimetry. These reductions in scan time could facilitate the routine implementation of post-LuPSMA SPECT/CT in clinical practice.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.